MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage genetic medicine company, has announced the pricing of an underwritten offering of 12,500,000 ordinary shares at $4.00 per share. The offering, expected to close on August 13, 2024, aims to raise $50 million in gross proceeds. Sanofi led the financing with a $30 million equity investment, joined by Perceptive Advisors and other institutional healthcare funds. BofA Securities is acting as the sole underwriter. The offering is made pursuant to an effective shelf registration statement filed with the SEC on December 21, 2023.